Edmonton, Alberta, Canada, June 15, 2021 -- On the heels of closing its Series A last month, Pacylex CEO Michael Weickert will present at The Biotechnology Innovation Organization (BIO) Digital 2021 International Convention as part of the Alberta Life Sciences Showcase event on Tuesday, June 15 at 3:00 – 5:30 PM (UTC-07:00) Mountain Time (US & Canada). This update will include progress towards the initiation of the first clinical trial with PCLX-001 in the next month.
Later this month, Dr. Luc Berthiaume, CSO of Pacylex, will present an overview of the journey of discovery to clinical trials in cancer patients of the NMT inhibitor, PCLX-001, at the FASEB (Federation of American Societies for Experimental Biology) Scientific Research Conference: The Protein Lipidation Conference: Enzymology, Signaling and Therapeutics.
FASEB Presentation Details:
Title of talk: “N-myristoyltransferase inhibitors for lymphoma and leukemia: our journey to clinical trials"
Date: June 30, 2021
Time: 10:55 am - 11:15 am EDT
PCLX-001 is a small molecule, first-in-class N-myristoyltransferase (NMT) inhibitor, originally developed by the University of Dundee Drug Discovery Unit as part of a program to treat African sleeping sickness funded by Wellcome Trust. Pacylex is developing PCLX-001, which has excellent oral bioavailability, to treat leukemia and lymphoma. PCLX-001 selectively kills cancer cells and completely regresses (eliminates) tumors in animal models of acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). PCLX-001 has also been shown to inhibit the growth of lung and breast cancer tumors in animal models. In leukemia, lymphoma and breast cancer patients, the level of NMT2 is correlated with survival, suggesting an important biological role in these cancers. In tests using cultured cancer cells in vitro, PCLX-001 is at least ten times as potent as ibrutinib (Imbruvica) and dasatinib (Sprycel), two clinically approved drugs currently used to treat hematologic malignancies.
Pacylex is a pharmaceutical company targeting hematologic and solid cancers with a new first-in-class therapeutic, headquartered in Edmonton, Alberta, Canada. Pacylex’s technology combines new insights from Dr. Luc Berthiaume of the University of Alberta, connecting myristoylation to cancer, with a family of high quality myristoylation inhibitors Pacylex licensed from the University of Dundee. PCLX-001 is the lead drug in a new class of NMT inhibitors, enabling Pacylex to exploit NMTs as new clinical targets for cancer treatment. Pacylex has received regulatory authorization to begin clinical studies in Canada in the spring of 2021 in diffuse large B-cell lymphoma and solid tumors. Pacylex is also receiving support from an Alberta Innovates AICE grant in 2020, and the research leading to this breakthrough was supported in part by the Alberta Cancer Foundation and the Cure Cancer Foundation.
For more information:
Pacylex Pharmaceuticals Contact: Michael J. Weickert
CEO, Pacylex Pharmaceuticals, Inc.
Twitter @Pacylex (https://twitter.com/pacylex)